Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 545Lung Neoplasms 240Small Cell Lung Carcinoma 106Mesothelioma, Malignant 57Adenocarcinoma of Lung 41Mesothelioma 35Neoplasms 27Neoplasm Metastasis 25Colorectal Neoplasms 22Carcinoma 17Squamous Cell Carcinoma of Head and Neck 15Ovarian Neoplasms 15Adenocarcinoma, Bronchiolo-Alveolar 14Parkinson Disease 4, Autosomal Dominant Lewy Body 13Stomach Neoplasms 12Pancreatic Neoplasms 12Non-Squamous Non-Small Cell Lung Cancer 12Head and Neck Neoplasms 12Pleural Effusion, Malignant 8Melanoma 8Breast Neoplasms 8Sarcoma 7Extensive Stage Small Cell Lung Cancer 7Triple Negative Breast Neoplasms 6Thymoma 6Solitary Fibrous Tumor, Pleural 6NSCLC 6Endometrial Neoplasms 6Drug-Related Side Effects and Adverse Reactions 6Colonic Neoplasms 6

Interventions

amatuximab 1Pemetrexed 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Severe combined immunodeficiency with sensitivity to ionizing radiation × Cisplatin × Thoracic × Clear all
NCT02357147 2020-03-17

ARTEMIS

Morphotek

Phase 2 Terminated
124 enrolled 10 charts
Other solid neoplasmThoracic

Severe combined immunodeficiency with sensitivity to ionizing radiation, Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡